| CDKN3 promotes tumor progression and confers cisplatin resistance via RAD51 in esophageal cancer | |
| Wang, Jiansong; Che, Wencheng; Wang, Weimin; Su, Gongzhang; Zhen, Tianchang; Jiang, Zhongmin | |
| 刊名 | CANCER MANAGEMENT AND RESEARCH
 |
| 2019 | |
| 卷号 | 11页码:3253-3264 |
| 关键词 | esophageal cancer chemoresistance CDKN3 RAD51 DNA damage repair |
| DOI | 10.2147/CMAR.S193793 |
| URL标识 | 查看原文 |
| 公开日期 | [db:dc_date_available] |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/4530831 |
| 专题 | 山东大学 |
| 作者单位 | 1.Weifang Med Univ, Grad Dept, Weifang 261031, Shandong, Peoples R China. 2.Zibo Cent Hosp, Dept Thorac |
| 推荐引用方式 GB/T 7714 | Wang, Jiansong,Che, Wencheng,Wang, Weimin,et al. CDKN3 promotes tumor progression and confers cisplatin resistance via RAD51 in esophageal cancer[J]. CANCER MANAGEMENT AND RESEARCH,2019,11:3253-3264. |
| APA | Wang, Jiansong,Che, Wencheng,Wang, Weimin,Su, Gongzhang,Zhen, Tianchang,&Jiang, Zhongmin.(2019).CDKN3 promotes tumor progression and confers cisplatin resistance via RAD51 in esophageal cancer.CANCER MANAGEMENT AND RESEARCH,11,3253-3264. |
| MLA | Wang, Jiansong,et al."CDKN3 promotes tumor progression and confers cisplatin resistance via RAD51 in esophageal cancer".CANCER MANAGEMENT AND RESEARCH 11(2019):3253-3264. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论